Glenmark gets USFDA tentative nod for oral contraceptives
Company will market oral contraceptive tablets Lo Loestrin Fe after receiving the final approval26-04-2016
26-04-2016
Glenmark Pharmaceuticals receives tentative ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.01 mg, Ethinyl Estradiol Tablets USP, 0.01 mg and Ferrous Fumarate Tablets, 75 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 26, 2016 titled "Glenmark Pharmaceuticals receives tentative ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.01 mg, Ethinyl Estradiol Tablets USP, 0.01 mg and Ferrous Fumarate Tablets, 75 mg".26-04-2016
Glenmark receives 3 observations from USFDA
The USFDA conveys its concerns on manufacturing practices for Glenmark's formulations facility at Pithampur21-04-2016
Clarification
Glenmark Pharmaceuticals Ltd has informed BSE regarding "Clarification on news item appearing in ET Now on April 21, 2016 in respect of the Company's Pithampur Plant".21-04-2016
Shareholding for the Period Ended March 31, 2016
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here12-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Glenmark Pharmaceuticals Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.07-04-2016
Glenmark receives US FDA approval for bendamustine hydrochloride injection
It is Glenmark's first injectable approval in the US28-03-2016
Glenmark Pharmaceuticals receives another two ANDA approvals from the U.S. FDA
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated March 28, 2016 titled "Glenmark Pharmaceuticals receives another two ANDA approvals from the U.S. FDA".28-03-2016
Glenmark Pharmaceuticals receives ANDA approval for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated March 28, 2016 titled "Glenmark Pharmaceuticals receives ANDA approval for Bendamustine Hydrochloride for Injection, 25 mg/vial and 100 mg/vial".28-03-2016
Glenmark Pharmaceuticals receives ANDA approval for Raloxifene Hydrochloride Tablets USP, 60 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated March 23, 2016, titled "Glenmark Pharmaceuticals receives ANDA approval for Raloxifene Hydrochloride Tablets USP, 60 mg".23-03-2016